Holen Sie sich die Stockscreener-App
1.11
8.82%
0.09
Schlusskurs vom Vortag:
$1.02
Offen:
$1.05
24-Stunden-Volumen:
35,453
Relative Volume:
0.68
Marktkapitalisierung:
$44.65M
Einnahmen:
$13.42M
Nettoeinkommen (Verlust:
$-73.35M
KGV:
-
EPS:
-
Netto-Cashflow:
$-56.34M
1W Leistung:
+21.64%
1M Leistung:
+23.47%
6M Leistung:
-11.20%
1J Leistung:
-67.83%
1-Tages-Spanne:
$1.02
$1.1144
1-Wochen-Bereich:
$0.88
$1.25
52-Wochen-Spanne:
$0.8008
$4.1591
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Firmenname
Barinthus Biotherapeutics Plc Adr
Sektor
Branche
Telefon
44 (0) 1865 818808
Adresse
UNIT 6-10, ZEUS BUILDING, DIDCOT
Vergleichen Sie BRNS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
1.11 | 44.65M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-25 | Eingeleitet | William Blair | Outperform |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Aktie (BRNS) Neueste Nachrichten
New trial shows promise for chronic hepatitis B treatment - Investing.com India
Barinthus Bio completes enrollment for two clinical trials - Investing.com India
Barinthus Bio intiates Phase 1 clinical trial of VTP-1000 for treatment of coeliac disease - European Pharmaceutical Manufacturer
Barinthus Bio launches Phase 1 celiac disease therapy trial - Investing.com
Barinthus Biotherapeutics Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease - Investing.com
Barinthus Biotherapeutics appoints new COO - Investing.com
BRNS Stock Touches 52-Week Low at $1.14 Amid Market Challenges - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ... - Benzinga
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket By ... - Investing.com UK
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Barinthus Bio refocuses on hepatitis B and celiac disease treatments By Investing.com - Investing.com
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
ANVS Stock Quote Price and Forecast - CNN
Vaccitech (VACC) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Finanzdaten der Barinthus Biotherapeutics Plc Adr-Aktie (BRNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):